(Q36292648)

13 August 2017

1 reference

title

Alefacept for psoriasis and psoriatic arthritis (English)

1 reference

13 August 2017

A B Gottlieb

1

1 reference

PMC publication ID

1766916

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Annals of the Rheumatic Diseases

13 August 2017

1 reference

13 August 2017

64 Suppl 4

1 reference

13 August 2017

iv58-60

1 reference

The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

Severe Psoriasis – Oral Therapy with a New Retinoid

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

Eruptive pseudoangiomatosis caused by an insect bite.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766916

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

22 September 2018

1 reference

12 December 2020

Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells

1 reference

12 December 2020

Alefacept in the treatment of psoriatic nail disease: a small case series

1 reference

12 December 2020

Remittive effects of intramuscular alefacept in psoriasis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2005.042655

1 reference

13 August 2017

1 reference

PMC publication ID

1766916

13 August 2017

PubMed publication ID

16239390

1 reference

PMC publication ID

1766916